 Canaccord Genuity TSX:CF, LSE:CF said it continued to believe that Zynerba Pharmaceuticals NASDAQ:ZYNE is undervalued after the company reported its fourth-quarter financial results that showed a 67.8 million cash runway to advance its flagship Zygel CBD Gel for Fragile X Syndrome. We continue to believe that Zynerba, at its enterprise value of around 20 million, remains undervalued as it is pursuing high-riskhigh-reward indications where the unmet need is high, Canaccord analysts wrote in a note. 